Use of Total Parenteral Nutrition (TPN) as a Vehicle for Drug Delivery

Hossamaldeen      Bakrey; Riya      Shivgotra; Abdulkadir      Abdu; Bindu      Soni; Navid Reza      Shahtaghia; Subheet Kumar      Jain; Shubham      Thakur
doi:10.2174/0113894501284598240226102943
Abstract

Total Parenteral Nutrition (TPN) is a method of providing nutrients directly into the bloodstream for individuals who are unable to meet their nutritional needs through the normal digestive process or gastrointestinal system. It provides macronutrients and micronutrients in a single container, reducing handling and contamination risks and making it more cost-effective. TPN has the potential to be used as a drug delivery system, with applications in combination therapies, personalized medicine, and integrating advanced technologies. It can enhance drug dosage precision and provide nutritional assistance, potentially reducing hospitalization and improving patient outcomes. However, implementing new applications requires thorough testing and regulatory approval. TPN could be particularly useful in pediatric and geriatric care and could also contribute to global health by combating malnutrition in areas with limited medical resources. Healthcare professionals prepare a sterile solution tailored to each patient's nutritional needs, and administration involves a central venous catheter. However, the simultaneous administration of medications with PN admixtures can result in pharmacological incompatibility, which can impact the stability of the oil-in-water system. The European Society for Clinical Nutrition and Metabolism and the American Society for Parenteral and Enteral Nutrition recommendations advise against including non-nutrient drugs in PN admixtures due to safety concerns. This review focuses on the utilization of Total Parenteral Nutrition (TPN) as a method for delivering drugs. It discusses the benefits and difficulties associated with its commercial application and offers suggestions for future research endeavors.
Keywords: Total Parenteral Nutrition (TPN), drug delivery, formulation, biocompatibility, stability, malnutrition.
« Previous Next »
Graphical Abstract

[1]
Stawny M, Olijarczyk R, Jaroszkiewicz E, Jelińska A. Pharmaceutical point of view on parenteral nutrition. ScientificWorldJournal  2013; 2013: 1-9.
 [http://dx.doi.org/10.1155/2013/415310] [PMID: 24453847]

[2]
Pironi L, Joly F, Forbes A, et al. Long-term follow-up of patients on home parenteral nutrition in Europe: Implications for intestinal transplantation. Gut  2011; 60(1): 17-25.
 [http://dx.doi.org/10.1136/gut.2010.223255] [PMID: 21068130]

[3]
Pironi L, Forbes A, Joly F, et al. Survival of patients identified as candidates for intestinal transplantation: A 3-year prospective follow-up. Gastroenterology  2008; 135(1): 61-71.
 [http://dx.doi.org/10.1053/j.gastro.2008.03.043] [PMID: 18471440]

[4]
Messing B, Joly F. Guidelines for management of home parenteral support in adult chronic intestinal failure patients. Gastroenterology  2006; 130(2): S43-51.
 [http://dx.doi.org/10.1053/j.gastro.2005.09.064] [PMID: 16473071]

[5]
Pironi L, Paganelli F, Labate AMM, et al. Safety and efficacy of home parenteral nutrition for chronic intestinal failure: A 16-year experience at a single centre. Dig Liver Dis  2003; 35(5): 314-24.
 [http://dx.doi.org/10.1016/S1590-8658(03)00074-4] [PMID: 12846403]

[6]
Boullata JI, Mirtallo JM, Sacks GS, et al. Parenteral nutrition compatibility and stability: A comprehensive review. JPEN J Parenter Enteral Nutr  2022; 46(2): 273-99.
 [http://dx.doi.org/10.1002/jpen.2306] [PMID: 34788478]

[7]
Flack HL, Gans JA, Serlick SE, Dudrick SJ. The current status of parenteral hyperalimentation. Am J Hosp Pharm  1971; 28(5): 326-35.
 [PMID: 4999686]

[8]
Mirtallo J, Canada T, Johnson D, et al. Safe practices for parenteral nutrition. JPEN J Parenter Enteral Nutr  2004; 28(6): S39-70.
 [http://dx.doi.org/10.1177/0148607104028006S39] [PMID: 15568296]

[9]
Worthington P, Balint J, Bechtold M, et al. When is parenteral nutrition appropriate? JPEN J Parenter Enteral Nutr  2017; 41(3): 324-77.
 [http://dx.doi.org/10.1177/0148607117695251] [PMID: 28333597]

[10]
Mirtallo JM, Participants PS. Consensus of parenteral nutrition safety issues and recommendations. JPEN J Parenter Enteral Nutr  2012; 36(2S): 62S.
 [http://dx.doi.org/10.1177/0148607111434782] [PMID: 22301332]

[11]
Athanasiou C, Hatziantoniou S, Skouroliakou M, Markantonis-Kyroudis S. Assessment of the physicochemical stability of all-in-one parenteral emulsions for neonates according to USP specifications. JPEN J Parenter Enteral Nutr  2014; 38(7): 867-72.
 [http://dx.doi.org/10.1177/0148607113499589] [PMID: 23976766]

[12]
Berlana D. Parenteral nutrition overview. Nutrients  2022; 14(21): 4480.
 [http://dx.doi.org/10.3390/nu14214480] [PMID: 36364743]

[13]
Singer P, Blaser AR, Berger MM, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr  2019; 38(1): 48-79.
 [http://dx.doi.org/10.1016/j.clnu.2018.08.037] [PMID: 30348463]

[14]
Compher C, Bingham AL, McCall M, et al. Guidelines for the provision of nutrition support therapy in the adult critically ill patient: The American Society for Parenteral and Enteral Nutrition. JPEN J Parenter Enteral Nutr  2022; 46(1): 12-41.
 [http://dx.doi.org/10.1002/jpen.2267] [PMID: 34784064]

[15]
Reber E, Messerli M, Stanga Z, Mühlebach S. Pharmaceutical aspects of artificial nutrition. J Clin Med  2019; 8(11): 2017.
 [http://dx.doi.org/10.3390/jcm8112017] [PMID: 31752291]

[16]
Dudrick SJ. History of parenteral nutrition. J Am Coll Nutr  2009; 28(3): 243-51.
 [http://dx.doi.org/10.1080/07315724.2009.10719778] [PMID: 20150597]

[17]
Nagar T, Ramakrishna JM, Reddy T, Turk I. Invasive pulmonary candidiasis in a patient requiring chronic total parenteral nutrition. ACG Case Rep J  2023; 10(9): e01138.
 [http://dx.doi.org/10.14309/crj.0000000000001138]

[18]
Wu L, Razavi T, Miller C, Khu K. Initiating home parenteral nutrition therapy in a patient at high risk of refeeding syndrome after COVID-19 infection. JPEN J Parenter Enteral Nutr  2023; S203-4.

[19]
Nakao Y, Sasanuma H, Sata N, et al. Factors associated with the need for long-term total parenteral nutrition in survivors of acute superior mesenteric artery occlusion. Eur J Trauma Emerg Surg  2023; 49(5): 2025-30.
 [http://dx.doi.org/10.1007/s00068-023-02281-1] [PMID: 37227462]

[20]
Stroe MS, Van Bockstal L, Valenzuela A, et al. Development of a neonatal Göttingen Minipig model for dose precision in perinatal asphyxia: Technical opportunities, challenges, and potential further steps. Front Pediatr  2023; 11: 1163100.
 [http://dx.doi.org/10.3389/fped.2023.1163100] [PMID: 37215599]

[21]
Katoue MG, Al-Taweel D, Matar KM, Kombian SB. Parenteral nutrition in hospital pharmacies. Int J Health Care Qual Assur  2016; 29(6): 664-74.
 [http://dx.doi.org/10.1108/IJHCQA-08-2015-0104] [PMID: 27298063]

[22]
Tanaka K, Ohkubo H, Yamamoto A, et al. Natural history of chronic intestinal pseudo-obstruction and need for palliative care. J Neurogastroenterol Motil  2023; 29(3): 378-87.
 [http://dx.doi.org/10.5056/jnm22152] [PMID: 37417265]

[23]
Bouchoud L, Fonzo-Christe C, Klingmüller M, Bonnabry P. Compatibility of intravenous medications with parenteral nutrition: in vitro evaluation. JPEN J Parenter Enteral Nutr  2013; 37(3): 416-24.
 [http://dx.doi.org/10.1177/0148607112464239] [PMID: 23112277]

[24]
Mühlebach SF. Diets and diet therapy: Parenteral nutrition. Reference Module in Food Science. Elsevier 2019.
 [http://dx.doi.org/10.1016/B978-0-08-100596-5.21937-9]

[25]
Riethmueller J, Junge S, Schroeter TW, et al. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection  2009; 37(5): 418-23.
 [http://dx.doi.org/10.1007/s15010-009-8116-5] [PMID: 19756419]

[26]
Korbila IP, Tansarli GS, Karageorgopoulos DE, Vardakas KZ, Falagas ME. Extended or continuous versus short-term intravenous infusion of cephalosporins: A meta-analysis. Expert Rev Anti Infect Ther  2013; 11(6): 585-95.
 [http://dx.doi.org/10.1586/eri.13.44] [PMID: 23750730]

[27]
Mühlebach S. Basics in clinical nutrition: Drugs and nutritional admixtures. E Spen Eur E J Clin Nutr Metab  2009; 4(3): e134-6.
 [http://dx.doi.org/10.1016/j.eclnm.2009.01.008]

[28]
Boullata JI, Gilbert K, Sacks G, et al. A.S.P.E.N. clinical guidelines: parenteral nutrition ordering, order review, compounding, labeling, and dispensing. JPEN J Parenter Enteral Nutr  2014; 38(3): 334-77.
 [http://dx.doi.org/10.1177/0148607114521833] [PMID: 24531708]

[29]
Sobotka L, Forbes A. Basics in clinical nutrition. Galen 2019.

[30]
Dettlaff K, Stawny M, Gostyńska A, Popielarz-Brzezińska M, Ogrodowczyk M. Compatibility of intravenous metronidazole with some all-in-one parenteral nutrition regimens. Nutrition  2021; 84: 111020.
 [http://dx.doi.org/10.1016/j.nut.2020.111020] [PMID: 33139150]

[31]
Archer SB, Burnett RJ, Fischer JE. Current uses and abuses of total parenteral nutrition. Adv Surg  1996; 29: 165-89.
 [PMID: 8720002]

[32]
Bettag J, Po L, Cunningham C, et al. Novel therapeutic approaches for mitigating complications in short bowel syndrome. Nutrients  2022; 14(21): 4660.
 [http://dx.doi.org/10.3390/nu14214660] [PMID: 36364922]

[33]
Cooper JL, Rosentreter RE, Filyk A, et al. Nutritional interventions in adult fibrostenotic Crohn’s disease: A systematic review. Front Nutr  2023; 10: 1017382.
 [http://dx.doi.org/10.3389/fnut.2023.1017382] [PMID: 36895272]

[34]
Torelli GF, Campos AC, Meguid MM. Use of TPN in terminally ill cancer patients. Nutrition  1999; 15(9): 665-7.
 [http://dx.doi.org/10.1016/S0899-9007(99)00118-5]

[35]
Ong XYS, Sultana R, Tan JWS, et al. The role of total parenteral nutrition in patients with peritoneal carcinomatosis: A systematic review and meta-analysis. Cancers  2021; 13(16): 4156.
 [http://dx.doi.org/10.3390/cancers13164156] [PMID: 34439309]

[36]
Bartın MK. Comparing total parenteral nutrition with other methods in treating chylotorax. J Cardiothorac Vasc Anesth  2023; 29(1)
 [http://dx.doi.org/10.14744/GKDAD.2023.57855]

[37]
Tang Q, Hong Z, Ren H, et al. Nutritional management of patients with enterocutaneous fistulas: Practice and progression. Front Nutr  2020; 7: 564379.
 [http://dx.doi.org/10.3389/fnut.2020.564379] [PMID: 33123545]

[38]
Cuerda C, Pironi L, Arends J, et al. ESPEN practical guideline: Clinical nutrition in chronic intestinal failure. Clin Nutr  2021; 40(9): 5196-220.
 [http://dx.doi.org/10.1016/j.clnu.2021.07.002] [PMID: 34479179]

[39]
Pironi L, Arends J, Baxter J, et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr  2015; 34(2): 171-80.
 [http://dx.doi.org/10.1016/j.clnu.2014.08.017] [PMID: 25311444]

[40]
Mueller CM, McClave SA, Kuhn JM. The ASPEN adult nutrition support core curriculum. ASPEN 2017.

[41]
Miao L, Zhang Y, Hu H, et al. Incidence and management of chylothorax after esophagectomy. Thorac Cancer  2015; 6(3): 354-8.
 [http://dx.doi.org/10.1111/1759-7714.12240] [PMID: 26273383]

[42]
Faienza MF, D’Amato E, Natale MP, et al. Metabolic bone disease of prematurity: Diagnosis and management. Front Pediatr  2019; 7: 143.
 [http://dx.doi.org/10.3389/fped.2019.00143] [PMID: 31032241]

[43]
Piper SN, Schade I, Beschmann RB, Maleck WH, Boldt J, Röhm KD. Hepatocellular integrity after parenteral nutrition: Comparison of a fish-oil-containing lipid emulsion with an olive-soybean oil-based lipid emulsion. Eur J Anaesthesiol  2009; 26(12): 1076-82.
 [http://dx.doi.org/10.1097/EJA.0b013e32832e08e0] [PMID: 19916246]

[44]
Antébi H, Mansoor O, Ferrier C, et al. Liver function and plasma antioxidant status in intensive care unit patients requiring total parenteral nutrition: Comparison of 2 fat emulsions. JPEN J Parenter Enteral Nutr  2004; 28(3): 142-8.
 [http://dx.doi.org/10.1177/0148607104028003142] [PMID: 15141405]

[45]
Schade I, Röhm KD, Schellhaass A, Mengistu A, Boldt J, Piper SN. Inflammatory response in patients requiring parenteral nutrition: Comparison of a new fish-oil-containing emulsion (SMOF®) versus an olive/soybean oil-based formula. Crit Care  2008; 12: P144.
 [http://dx.doi.org/10.1186/cc6365]

[46]
Grimm H, Mertes N, Goeters C, et al. Improved fatty acid and leukotriene pattern with a novel lipid emulsion in surgical patients. Eur J Nutr  2006; 45(1): 55-60.
 [http://dx.doi.org/10.1007/s00394-005-0573-8] [PMID: 16041475]

[47]
Mertes N, Grimm H, Fürst P, Stehle P. Safety and efficacy of a new parenteral lipid emulsion (SMOFlipid) in surgical patients: A randomized, double-blind, multicenter study. Ann Nutr Metab  2006; 50(3): 253-9.
 [http://dx.doi.org/10.1159/000091683] [PMID: 16508253]

[48]
Tomsits E, Pataki M, Tölgyesi A, Fekete G, Rischak K, Szollár L. Safety and efficacy of a lipid emulsion containing a mixture of soybean oil, medium-chain triglycerides, olive oil, and fish oil: A randomised, double-blind clinical trial in premature infants requiring parenteral nutrition. J Pediatr Gastroenterol Nutr  2010; 51(4): 514-21.
 [http://dx.doi.org/10.1097/MPG.0b013e3181de210c] [PMID: 20531018]

[49]
Klek S, Chambrier C, Singer P, et al. Four-week parenteral nutrition using a third generation lipid emulsion (SMOFlipid) - A double-blind, randomised, multicentre study in adults. Clin Nutr  2013; 32(2): 224-31.
 [http://dx.doi.org/10.1016/j.clnu.2012.06.011] [PMID: 22796064]

[50]
Singer P, Berger MM, Van den Berghe G, et al. ESPEN guidelines on parenteral nutrition: Intensive care. Clin Nutr  2009; 28(4): 387-400.
 [http://dx.doi.org/10.1016/j.clnu.2009.04.024] [PMID: 19505748]

[51]
Caresta E, Pierro A, Chowdhury M, Peters MJ, Piastra M, Eaton S. Oxidation of intravenous lipid in infants and children with systemic inflammatory response syndrome and sepsis. Pediatr Res  2007; 61(2): 228-32.
 [http://dx.doi.org/10.1203/01.pdr.0000252441.91671.e5] [PMID: 17237727]

[52]
Socha P, Koletzko B, Demmelmair H, et al. Short-term effects of parenteral nutrition of cholestatic infants with lipid emulsions based on medium-chain and long-chain triacylglycerols. Nutrition  2007; 23(2): 121-6.
 [http://dx.doi.org/10.1016/j.nut.2006.10.009] [PMID: 17234505]

[53]
Webb AN, Hardy P, Peterkin M, et al. Tolerability and safety of olive oil-based lipid emulsion in critically ill neonates: A blinded randomized trial. Nutrition  2008; 24(11-12): 1057-64.
 [http://dx.doi.org/10.1016/j.nut.2008.05.004] [PMID: 18619813]

[54]
Mateu-de Antonio J, Grau S, Luque S, Marín-Casino M, Albert I, Ribes E. Comparative effects of olive oil-based and soyabean oil-based emulsions on infection rate and leucocyte count in critically ill patients receiving parenteral nutrition. Br J Nutr  2008; 99(4): 846-54.
 [http://dx.doi.org/10.1017/S0007114507837433] [PMID: 17916276]

[55]
Braga M, Ljungqvist O, Soeters P, Fearon K, Weimann A, Bozzetti F. ESPEN guidelines on parenteral nutrition: Surgery. Clin Nutr  2009; 28(4): 378-86.
 [http://dx.doi.org/10.1016/j.clnu.2009.04.002] [PMID: 19464088]

[56]
Ziegler TR. Parenteral nutrition in the critically ill patient. N Engl J Med  2009; 361(11): 1088-97.
 [http://dx.doi.org/10.1056/NEJMct0806956] [PMID: 19741230]

[57]
Huston R, Christensen J, Alshahrani S, Mohamed S, Heisel C. Calcium chloride and calcium gluconate in neonatal parenteral nutrition solutions without cysteine: Compatibility studies using laser light obscuration methodology. Nutrients  2018; 10(2): 208.
 [http://dx.doi.org/10.3390/nu10020208] [PMID: 29443921]

[58]
De Vizia B, Raia V, Spano C, Pavlidis C, Coruzzo A, Alessio M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. JPEN J Parenter Enteral Nutr  2003; 27(1): 52-7.
 [http://dx.doi.org/10.1177/014860710302700152] [PMID: 12549599]

[59]
Grecu I, Mirea L, Grintescu I. Parenteral fish oil supplementation in patients with abdominal sepsis. Am J Clin Nutr  2003; S23(22)
 [http://dx.doi.org/10.1093/burnst/tkac012]

[60]
Grimble R. Use of n-3 fatty acid-containing lipid emulsions in the intensive care unit environment: The scientist’s view. Am J Clin Nutr  2002; 21(Suppl. 2): 15-20.
 [http://dx.doi.org/10.1097/CCM.0000000000000612]

[61]
Heller AR, Rössel T, Gottschlich B, et al. Omega-3 fatty acids improve liver and pancreas function in postoperative cancer patients. Int J Cancer  2004; 111(4): 611-6.
 [http://dx.doi.org/10.1002/ijc.20291] [PMID: 15239141]

[62]
Bonnes SL, Austin KE, Carnell JJ, Salonen BR. Premixed vs compounded parenteral nutrition: Effects of total parenteral nutrition shortage on clinical practice. Curr Nutr Rep  2019; 8(4): 397-401.
 [http://dx.doi.org/10.1007/s13668-019-00291-3] [PMID: 31691201]

[63]
Chang RWS, Hatton I, Henley J, Richardson R, Egail S. Total parenteral nutrition: A four-year audit. Br J Surg  2005; 73(8): 656-8.
 [http://dx.doi.org/10.1002/bjs.1800730827] [PMID: 3091133]

[64]
Aihara R, Schoepfel SL, Curtis AR, et al. Guidelines for improving nutritional delivery in the intensive care unit. J Healthc Qual  2002; 24(2): 22-9.
 [http://dx.doi.org/10.1111/j.1945-1474.2002.tb00415.x] [PMID: 11942154]

[65]
Faber EM. Program for training staff pharmacists in total parenteral nutrition. Am J Health Syst Pharm  1991; 48(5): 980-6.
 [http://dx.doi.org/10.1093/ajhp/48.5.980] [PMID: 1906679]

[66]
Ross EL, Petty K, Salinas A, Her C, Carpenter JF. Physical compatibility of medications with concentrated neonatal and pediatric parenteral nutrition: A simulated Y-site drug compatibility study. JPEN J Parenter Enteral Nutr  2023; 47(3): 372-81.
 [http://dx.doi.org/10.1002/jpen.2469] [PMID: 36582024]

[67]
Ste-Marie MT. Use of Travasol in paediatric patients. Proceedings of an International Symposium held in Bermuda  16–19th May; 1977; pp. 1977; 293-300.

[68]
Tuvdendorj D, Chinkes DL, Zhang XJ, et al. Long-term oxandrolone treatment increases muscle protein net deposition via improving amino acid utilization in pediatric patients 6 months after burn injury. Surgery  2011; 149(5): 645-53.
 [http://dx.doi.org/10.1016/j.surg.2010.12.006] [PMID: 21333314]

[69]
Laine L, Shulman RJ, Pitre D, Lifschitz CH, Adams J. Cysteine usage increases the need for acetate in neonates who receive total parenteral nutrition. Am J Clin Nutr  1991; 54(3): 565-7.
 [http://dx.doi.org/10.1093/ajcn/54.3.565] [PMID: 1908633]

[70]
Malloy MH, Rassin DK. Cysteine supplementation of total parenteral nutrition: The effect in beagle pups. Pediatr Res  1984; 18(8): 747-51.
 [http://dx.doi.org/10.1203/00006450-198408000-00015] [PMID: 6433317]

[71]
Wright K, Ernst KD, Gaylord MS, Dawson JP, Burnette TM. Increased incidence of parenteral nutrition-associated cholestasis with aminosyn PF compared to trophamine. J Perinatol  2003; 23(6): 444-50.
 [http://dx.doi.org/10.1038/sj.jp.7210965] [PMID: 13679929]

[72]
Sunehag AL. The role of parenteral lipids in supporting gluconeogenesis in very premature infants. Pediatr Res  2003; 54(4): 480-6.
 [http://dx.doi.org/10.1203/01.PDR.0000081298.06751.76] [PMID: 12815113]

[73]
Hemmann B, Josephsen J, Hillman N, et al. Impact of early fortification in very low birth weight infants on the incidence of malnutrition during a trophamine shortage. J Pediatr Pharmacol Ther  2022; 27(3): 237-43.
 [http://dx.doi.org/10.5863/1551-6776-27.3.237] [PMID: 35350152]

[74]
Migaki EA, Melhart BJ, Dewar CJ, Huston RK. Calcium chloride and sodium phosphate in neonatal parenteral nutrition containing TrophAmine: Precipitation studies and aluminum content. JPEN J Parenter Enteral Nutr  2012; 36(4): 470-5.
 [http://dx.doi.org/10.1177/0148607111420154] [PMID: 22245762]

[75]
Leenders EK. Low-versus high-dose and early versus late parenteral amino-acid administration in very-low-birth-weight infants: A systematic review and meta-analysis. Neonatology  2018; 113(3): 187-205.
 [http://dx.doi.org/10.1159/000481192] [PMID: 29268262]

[76]
Sommer I, Schwebel H, Adamo V, Bonnabry P, Bouchoud L, Sadeghipour F. Stability of N-acetylcysteine (NAC) in standardized pediatric parenteral nutrition and evaluation of N, N-diacetylcystine (DAC) formation. Nutrients  2020; 12(6): 1849.
 [http://dx.doi.org/10.3390/nu12061849] [PMID: 32575864]

[77]
Hardy G, Ball P, McElroy B. Basic principles for compounding all-in-one parenteral nutrition admixtures. Curr Opin Clin Nutr Metab Care  1998; 1(3): 291-6.
 [http://dx.doi.org/10.1097/00075197-199805000-00010] [PMID: 10565363]

[78]
Sweetman SC, Sweezde PC. Antidiabetic drugs. Martindale: The complete drug reference.  (34th ed..). Pharmaceutical Press London 2005; p. 453.

[79]
Remington JP. Remington: The science and practice of pharmacy. Lippincott Williams & Wilkins 2006.

[80]
Mirtallo JM, Ayers P, Boullata J, et al. ASPEN lipid injectable emulsion safety recommendations, part 1: Background and adult considerations. Nutr Clin Pract  2020; 35(5): 769-82.
 [http://dx.doi.org/10.1002/ncp.10496] [PMID: 32460429]

[81]
Anez-Bustillos L, Dao DT, Baker MA, Fell GL, Puder M, Gura KM. Intravenous fat emulsion formulations for the adult and pediatric patient: Understanding the differences. Nutr Clin Pract  2016; 31(5): 596-609.
 [http://dx.doi.org/10.1177/0884533616662996] [PMID: 27533942]

[82]
Calder PC, Waitzberg DL, Klek S, Martindale RG. Lipids in parenteral nutrition: Biological aspects. JPEN J Parenter Enteral Nutr  2020; 44(S1): S21-7.
 [http://dx.doi.org/10.1002/jpen.1756] [PMID: 32049394]

[83]
Weinstein MM, Siegel FP, Blake MI. Formulation of a stable trace element solution for TPN. Am J Hosp Pharm  1980; 37(12): 1620.
 [http://dx.doi.org/10.1093/ajhp/37.12.1620]

[84]
Vanek VW, Borum P, Buchman A, et al. A.S.P.E.N. position paper: Recommendations for changes in commercially available parenteral multivitamin and multi-trace element products. Nutr Clin Pract  2012; 27(4): 440-91.
 [http://dx.doi.org/10.1177/0884533612446706] [PMID: 22730042]

[85]
Jin J, Mulesa L, Carrilero Rouillet M. Trace elements in parenteral nutrition: Considerations for the prescribing clinician. Nutrients  2017; 9(5): 440.
 [http://dx.doi.org/10.3390/nu9050440] [PMID: 28452962]

[86]
Aschner JL, Maitre NL. Manganese and parenteral nutrition. Manganese in Health and Disease.  Royal Society of Chemistry 2014; pp. 403-25.
 [http://dx.doi.org/10.1039/9781782622383-00403]

[87]
Zinc sulfate insert - American regent.  Available from:https://www.americanregent.com/media/3086/zinc-sulfate-insert-in8005-rev-10-2020.pdf (Accessed: 20 September 2023). 

[88]
INFUVITE Pediatric - Multiple Vitamins Baxter Healthcare Corporation.  Available from:www.accessdata.fda.gov/drugsatfda_docs/label/2008/021265s015lbl.pdf (Accessed 20 Sept. 2023). 

[89]
Kalikstad B, Skjerdal A, Hansen TWR. Compatibility of drug infusions in the NICU. Arch Dis Child  2010; 95(9): 745-8.
 [http://dx.doi.org/10.1136/adc.2009.174268] [PMID: 20570841]

[90]
Katoue MG, Al-Taweel D. Role of the pharmacist in parenteral nutrition therapy: Challenges and opportunities to implement pharmaceutical care in Kuwait. Pharma Prac  2016; 142
 [http://dx.doi.org/10.18549/PharmPract.2016.02.680]

[91]
Keaney TJ, Enfanto RM, Sheridan RL. Drug delivery dilemmas: Compatibility of morphine, midazolam and dopamine with TPN infused through a single lumen. J Burn Care Rehabil  2001; 22: S165.
 [http://dx.doi.org/10.1097/00004630-200103002-00236]

[92]
Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res  2004; 21(2): 201-30.
 [http://dx.doi.org/10.1023/B:PHAM.0000016235.32639.23] [PMID: 15032302]

[93]
Realdon N, Zennaro L, Perin F, et al. Surface characterisation of bags for total parenteral nutrition by tensiometry and atomic force microscopy. Int J Pharm  2003; 265((1-2)): 27-35.
 [http://dx.doi.org/10.1016/S0378-5173(03)00359-4]

[94]
Durand-Zaleski I, Delaunay L, Langeron O, Belda E, Astier A, Brun-Buisson C. Infection risk and cost-effectiveness of commercial bags or glass bottles for total parenteral nutrition. Infect Control Hosp Epidemiol  1997; 18(3): 183-8.
 [http://dx.doi.org/10.2307/30141979] [PMID: 9090546]

[95]
Mühlebach S. Practical aspects of multichamber bags for total parenteral nutrition. Curr Opin Clin Nutr  2005; 8(3): 291-5.
 [http://dx.doi.org/10.1097/01.mco.0000165008.47073.ba]

[96]
Niemiec PW Jr, Vanderveen TW. Compatibility considerations in parenteral nutrient solutions. Am J Health Syst Pharm  1984; 41(5): 893-911.
 [http://dx.doi.org/10.1093/ajhp/41.5.893] [PMID: 6328980]

[97]
Driscoll DF, Baptista RJ, Mitrano FP, Mascioli EA, Blackburn GL, Bistrian BR. Parenteral nutrient admixtures as drug vehicles: Theory and practice in the critical care setting. DICP  1991; 25(3): 276-83.
 [http://dx.doi.org/10.1177/106002809102500312] [PMID: 1674183]

[98]
Newton DW. Y-site compatibility of intravenous drugs with parenteral nutrition. JPEN J Parenter Enteral Nutr  2013; 37(3): 297-9.
 [http://dx.doi.org/10.1177/0148607112465653] [PMID: 23114264]

[99]
Ayers P, Adams S, Boullata J, et al. A.S.P.E.N. parenteral nutrition safety consensus recommendations. JPEN J Parenter Enteral Nutr  2014; 38(3): 296-333.
 [http://dx.doi.org/10.1177/0148607113511992] [PMID: 24280129]

[100]
Stawny M, Gostyńska A, Dettlaff K, Jelińska A, Główka E, Ogrodowczyk M. Effect of lipid emulsion on stability of ampicillin in total parenteral nutrition. Nutrients  2019; 11(3): 559.
 [http://dx.doi.org/10.3390/nu11030559] [PMID: 30845675]

[101]
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN J Parenter Enteral Nutr  1999; 23(2): 67-74.
 [http://dx.doi.org/10.1177/014860719902300267] [PMID: 10081995]

[102]
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health Syst Pharm  1997; 54(11): 1295-300.
 [http://dx.doi.org/10.1093/ajhp/54.11.1295] [PMID: 9179351]

[103]
Stawny M, Gostyńska A, Nadolna M, Jelińska A. Safe practice of Y-site drug administration: The case of colistin and parenteral nutrition. Pharmaceutics  2020; 12(3): 292.
 [http://dx.doi.org/10.3390/pharmaceutics12030292] [PMID: 32213881]

[104]
Staven V, Iqbal H, Wang S, Grønlie I, Tho I. Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents. J Pharm Pharmacol  2017; 69(4): 448-62.
 [http://dx.doi.org/10.1111/jphp.12647] [PMID: 27714809]

[105]
Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health Syst Pharm  1996; 53(21): 2611-3.
 [http://dx.doi.org/10.1093/ajhp/53.21.2611] [PMID: 8913390]

[106]
Watrobska-Swietlikowska D, Pietka M, Klek S. Evaluation of Y-site compatibility of home total parenteral nutrition and intravenous loop diuretics. Medicine  2019; 98(21): e15747.
 [http://dx.doi.org/10.1097/MD.0000000000015747] [PMID: 31124957]

[107]
Ross EL, Salinas A, Petty K, Her C, Carpenter JF. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing. Am J Health Syst Pharm  2020; 77(23): 1980-5.
 [http://dx.doi.org/10.1093/ajhp/zxaa299] [PMID: 32974650]

[108]
Braunschweig C, Liang H, Sheean P. Indications for administration of parenteral nutrition in adults. Nutr Clin Pract  2004; 19(3): 255-62.
 [http://dx.doi.org/10.1177/0115426504019003255] [PMID: 16215113]

[109]
Pierre J, Mims T, Kumari R, et al. Impact of total parenteral nutrition and antibiotics on hepatic and intestinal homeostasis in pediatric murine model. Physiology  2023; 38(S1): 5663725.
 [http://dx.doi.org/10.1152/physiol.2023.38.S1.5663725]

[110]
Kim SH, Mun SJ, Kang JS, Moon C, Kim HT, Lee HY. Multifaceted evaluation of antibiotic therapy as a factor associated with candidemia in non-neutropenic patients. J Fungi  2023; 9(2): 270.
 [http://dx.doi.org/10.3390/jof9020270] [PMID: 36836385]

[111]
Tomczak S, Chmielewski M, Szkudlarek J, Jelińska A. Antiemetic drugs compatibility evaluation with paediatric parenteral nutrition admixtures. Pharmaceutics  2023; 15(8): 2143.
 [http://dx.doi.org/10.3390/pharmaceutics15082143] [PMID: 37631357]

[112]
Inayat-Hussain A, Falck H, Oorschot S, Picardo S, So K. Peripheral parenteral nutrition: An evaluation of its use, safety and cost implications in a tertiary hospital setting. Clin Nutr ESPEN  2023; 56: 215-21.
 [http://dx.doi.org/10.1016/j.clnesp.2023.05.020] [PMID: 37344076]

[113]
Rubino M, Jin J, Gramlich L. Safety and impact of peripheral parenteral nutrition on nutrient delivery in patients with nutrition risk: A prospective observational study. Nutr Clin Pract  2022; 37(5): 1162-71.
 [http://dx.doi.org/10.1002/ncp.10764] [PMID: 34520590]

[114]
Farhan M, McCallion N, Bennett J, Cram A, O’Brien F. Stability and compatibility of parenteral nutrition solutions; a review of influencing factors. Eur J Pharm Biopharm  2023; 187: 87-95.
 [http://dx.doi.org/10.1016/j.ejpb.2023.04.002] [PMID: 37061100]

[115]
Gostyńska A, Dettlaff K, Jelińska A, Stawny M. Improving the safety of clinical management of COVID-19 patients receiving aminoglycosides and parenteral nutrition: Y-site compatibility studies. J Pharm Sci  2023; 112(10): 2597-603.
 [http://dx.doi.org/10.1016/j.xphs.2023.08.007] [PMID: 37595749]

[116]
Mays A, Ayers P, Monczka J, Cober MP. Safety in parenteral nutrition compounding. Nutr Clin Pract  2023; 38(6): 1253-62.
 [http://dx.doi.org/10.1002/ncp.11064] [PMID: 37584457]

[117]
Pettit J. Assessment of the infant with a peripheral intravenous device. Adv Neonatal Care  2003; 3(5): 230-40.
 [http://dx.doi.org/10.1053/S1536-0903(03)00171-1] [PMID: 14648520]

[118]
Piper R, Carr PJ, Kelsey LJ, Bulmer AC, Keogh S, Doyle BJ. The mechanistic causes of peripheral intravenous catheter failure based on a parametric computational study. Sci Rep  2018; 8(1): 3441.
 [http://dx.doi.org/10.1038/s41598-018-21617-1] [PMID: 29467481]

[119]
Tabor E. Tutorial on how the US Food and Drug Administration regulates parenteral nutrition products. JPEN J Parenter Enteral Nutr  2020; 44(2): 174-81.
 [http://dx.doi.org/10.1002/jpen.1752] [PMID: 31971272]

[120]
Mirtallo JM. Drug-nutrient interactions in patients receiving parenteral nutrition. Handbook of Drug-Nutrient Interactions. Humana Press 2010.

[121]
Hardin TC, Clibon U, Page CP, Cruz AB Jr. Compatibility of 5-fluorouracil and total parenteral nutrition solutions. JPEN J Parenter Enteral Nutr  1982; 6(2): 163-5.
 [http://dx.doi.org/10.1177/0148607182006002163] [PMID: 6808179]

[122]
Tomczak S, Stawny M, Dettlaff K, Kieliszek M, Słomińska D, Jelińska A. Physicochemical compatibility and stability of linezolid with parenteral nutrition. Molecules  2019; 24(7): 1242.
 [http://dx.doi.org/10.3390/molecules24071242] [PMID: 30934964]

[123]
Baptista RJ. Role of histamine (H2)-receptor antagonists in total parenteral nutrition patients. Am J Med  1987; 83(6): 53-7.

[124]
Schilling CG, Watson DM, McCoy HG, Uden DL. Stability and delivery of vancomycin hydrochloride when admixed in a total parenteral nutrition solution. JPEN J Parenter Enteral Nutr  1989; 13(1): 63-4.
 [http://dx.doi.org/10.1177/014860718901300163] [PMID: 2494369]

[125]
Said Suliman A, Tom R, Palmer K, et al. Development, characterization and stability evaluation of ciprofloxacin-loaded parenteral nutrition nanoemulsions. Pharm Dev Technol  2020; 255: 579-87.
 [http://dx.doi.org/10.1080/10837450.2020.1720237]

[126]
Aeberhard C, Steuer C, Saxer C, Huber A, Stanga Z, Mühlebach S. Physicochemical stability and compatibility testing of levetiracetam in all-in-one parenteral nutrition admixtures in daily practice. Eur J Pharm Sci  2017; 96: 449-55.
 [http://dx.doi.org/10.1016/j.ejps.2016.10.015] [PMID: 27742594]

[127]
Tomczak S, Stawny M, Jelińska A. Co-administration of drugs and parenteral nutrition: in vitro compatibility studies of loop diuretics for safer clinical practice. Pharmaceutics  2020; 12(11): 1092.
 [http://dx.doi.org/10.3390/pharmaceutics12111092] [PMID: 33202945]

[128]
Dianzani C, Monge C, Miglio G, et al. Nanoemulsions as delivery systems for poly-chemotherapy aiming at melanoma treatment. Cancers  2020; 12(5): 1198.
 [http://dx.doi.org/10.3390/cancers12051198] [PMID: 32397484]

[129]
Najlah M, Kadam A, Wan KW, Ahmed W, Taylor KMG, Elhissi AMA. Novel paclitaxel formulations solubilized by parenteral nutrition nanoemulsions for application against glioma cell lines. Int J Pharm  2016; 506(1-2): 102-9.
 [http://dx.doi.org/10.1016/j.ijpharm.2016.04.027] [PMID: 27107899]

[130]
Reber E, Neyer P, Schönenberger KA, et al. Physicochemical stability and compatibility testing of voriconazole in all-in-one parenteral nutrition admixtures. Pharmaceutics  2021; 13(9): 1447.
 [http://dx.doi.org/10.3390/pharmaceutics13091447] [PMID: 34575522]

[131]
a) Cardona D, Nadal M, Estelrich J, Mangues MA. Review of drug stability in parenteral nutrition admixtures. E Spen Eur E J Clin Nutr Metab  2013; 8(4): e135-40.b) Sabin P, Monterde J, Cardona D, Lorente L, Pastor C. Incompatibilities between drugs and parenteral nutrition. Preliminary study. Farm Clin 1985; 2: 12-20.. 
 [http://dx.doi.org/10.1016/j.clnme.2013.06.001]

[132]
Jandot E, Savelli M, Pinte G, Sutherland A, Quessada T, Valla FV. Supplementations of industrial multichamber parenteral nutrition bags in critically ill children: Safety of the practice. Nutr Clin Pract  2023; 38(3): 698-706.
 [http://dx.doi.org/10.1002/ncp.10935] [PMID: 36420832]

[133]
Driscoll DF, Ling PR, Silvestri AP, Bistrian BR. Fine vs. coarse complete all-in-one admixture infusions over 96 hours in rats: Fat globule size and hepatic function. Clin Nutr  2008; 27(6): 889-94.
 [http://dx.doi.org/10.1016/j.clnu.2008.08.011]

[134]
Driscoll DF, Ling PR, Andersson C, Bistrian BR. Hepatic indicators of oxidative stress and tissue damage accompanied by systemic inflammation in rats following a 24-hour infusion of an unstable lipid emulsion admixture. JPEN J Parenter Enteral Nutr  2009; 33(3): 327-35.
 [http://dx.doi.org/10.1177/0148607108327155] [PMID: 19221047]

[135]
Muntada E, Masso´ J, Del Pozo A, et al. Compatibility of drugs with total nutrient admixtures (TNA) containing different lipid emulsions. Clin Nutr  2003; 22(22): S102.
 [http://dx.doi.org/10.1016/S0261-5614(03)80382-5]

[136]
Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health Syst Pharm  1997; 54(2): 181-4.
 [http://dx.doi.org/10.1093/ajhp/54.2.181]

[137]
Husson E, Crauste-Manciet S, Hadj-Salah E, Seguier JC, Brossard D. Compatibility of parenteral drugs with commercialized total parenteral admixtures: Injection of drug inside the admixtures. E Spen Eur E J Clin Nutr Metab  2003; 17(1): 8-14.

[138]
Balet A, Cardona D, Pastor C, Márquez M. Estabilidad “in vitro” de la amicacina y ciprofloxacina administradas en “Y” con dos nutriciones parenterales totales (NPT) de diferentes pH. Nutr Hosp  1990; 5(2): 108-11.
 [PMID: 2127703]

[139]
Bullock L, Clark JH, Fitzgerald JF, et al. The stability of amikacin, gentamicin, and tobramycin in total nutrient admixtures. JPEN J Parenter Enteral Nutr  1989; 13(5): 505-9.
 [http://dx.doi.org/10.1177/0148607189013005505] [PMID: 2514291]

[140]
Bassons T, Sanchez J, Bassas L. Insulina recuperada según los componentes de la nutrición parenteral. Rev SENPE  1985; 4(1): 93-9.

[141]
Ciszewska M, Knyt A, Kopec B, Pertkiewicz M. Insulin availability from all in one and fat-free nutrients admixtures. Clin Nutr  1994; 13: 56.
 [http://dx.doi.org/10.1016/0261-5614(94)90279-8]

[142]
Jeppsson RI, Sjöberg B. Compatibility of parenteral nutrition solutions when mixed in a plastic bag. Clin Nutr  1984; 2((3-4)): 149-58.
 [http://dx.doi.org/10.1016/0261-5614(84)90018-9]

[143]
García-Beltrán L, Martínez J, Morón A, Pou L, Sabín P. Estabilidad de la aminofilina en emulsiones de nutrición parenteral. Farm Clin  1986; 3(2): 96-102.

[144]
Andreu A, Cardona D, Pastor C, Bonal J. Intravenous aminophylline: in vitro stability in fat-containing TPN. Ann Pharmacother  1992; 26(1): 127-8.
 [http://dx.doi.org/10.1177/106002809202600125] [PMID: 1606335]

[145]
Albiñana MS, Carlos R, Campo M, Manzanares C, Gomis P. Estabilidad de teofilina en bolsas de nutrición parenteral unicapa y multicapa. Nutr Hosp  2001; 16(23): e6.

[146]
Massó J, Benarroch G, Jolonch P, Cusó E, Pastor C, Piera C. Digoxin stability, recovery and clinical use in TPN with lipids. Clin Nutr  1987; 6: 81.
 [http://dx.doi.org/10.1016/0261-5614(87)90214-7]

[147]
Ritchie DJ, Holstad SG, Westrich TJ, Hirsch JD, O'Dorisio TM. Activity of octreotide acetate in a total nutrient admixture. Am J Health Syst Pharm  1991; 4810. : 2172-5.
 [http://dx.doi.org/10.1093/ajhp/48.10.2172]

[148]
Pertkiewicz M, Cosslett A, Mühlebach S, Dudrick SJ. Basics in clinical nutrition: Stability of parenteral nutrition admixtures. E Spen Eur E J Clin Nutr Metab  2009; 4(3): e117-9.
 [http://dx.doi.org/10.1016/j.eclnm.2009.01.010]

[149]
Staven V, Wang S, Grønlie I, Tho I. Physical stability of an all-in-one parenteral nutrition admixture for preterm infants upon mixing with micronutrients and drugs. Eur J Hosp Pharm Sci Pract  2020; 27(1): 36-42.
 [http://dx.doi.org/10.1136/ejhpharm-2018-001562] [PMID: 32064087]

[150]
Kumar J, Teckman J. Controversies in the mechanism of total parenteral nutrition induced pathology. Children  2015; 2(3): 358-70.
 [http://dx.doi.org/10.3390/children2030358] [PMID: 27417369]

[151]
Gervasio J. Total nutrient admixtures (3-in-1): Pros vs cons for adults. Nutr Clin Pract  2015; 30(3): 331-5.
 [http://dx.doi.org/10.1177/0884533615578458] [PMID: 25855093]

[152]
Slattery E, Rumore MM, Douglas JS, Seres DS. 3-in-1 vs 2-in-1 parenteral nutrition in adults: A review. Nutr Clin Pract  2014; 29(5): 631-5.
 [http://dx.doi.org/10.1177/0884533614533611] [PMID: 25606645]

[153]
Murphy S, Craig DQM, Murphy A. An investigation into the physical stability of a neonatal parenteral nutrition formulation. Acta Paediatr  1996; 85(12): 1483-6.
 [http://dx.doi.org/10.1111/j.1651-2227.1996.tb13956.x] [PMID: 9001662]

[154]
Gulati N, Gupta H. Parenteral drug delivery: A review. Recent Pat Drug Deliv Formul  2011; 5(2): 133-45.
 [http://dx.doi.org/10.2174/187221111795471391] [PMID: 21453250]

[155]
Aulton ME, Taylor KM. Powder flow. Elsevier 2013.

[156]
Florence AT, Attwood D. Physicochemical principles of pharmacy: In manufacture, formulation and clinical use. Am J Health Syst Pharm 2015.

[157]
Mirtallo JM. Parenteral nutrition therapy: Assessment tools and guidelines. 2023. Available from:https://www.pharmacypracticenews.com/Review-Articles/Article/12-20/Parenteral-Nutrition-Therapy-Assessment-Tools-and-Guidelines/61246?sub=9B317915BCD96AA09E56EC45C02A5033613A46CEF93A48CCDB5E97523DB18&enl=true&dgid=--DGID--

[158]
Rombeau JL, Caldwell MD. Clinical nutrition: Parenteral nutrition.  WB Saunders Company 1993; p. 19941406884.

[159]
To vs en ML, Smistad G, Bjerke TM, Tønnesen HH, Kristensen S. Physicochemical stability of emulsions and admixtures for parenteral nutrition during irradiation by glass-filtered daylight at standardized conditions. J Drug Deliv Sci Technol  2015; 693: 346-54.
 [http://dx.doi.org/10.5731/pdajpst.2015.01036]

[160]
Unger N, Holzgrabe U. Stability and assessment of amino acids in parenteral nutrition solutions. J Pharm Biomed Anal  2018; 147(147): 125-39.
 [http://dx.doi.org/10.1016/j.jpba.2017.07.064] [PMID: 28797955]

[161]
Baxter JH. Free amino acid stability in reducing sugar systems. J Food Sci  1995; 60(2): 405-8.
 [http://dx.doi.org/10.1111/j.1365-2621.1995.tb05682.x]

[162]
Forchielli ML, Bongiovanni F, Platé L, et al. Insulin instability in parenteral nutrition admixtures. JPEN J Parenter Enteral Nutr  2018; 42(5): 907-12.
 [http://dx.doi.org/10.1002/jpen.1024] [PMID: 30001464]

[163]
Fry LK, Stegink LD. Formation of Maillard reaction products in parenteral alimentation solutions. J Nutr  1982; 112(8): 1631-7.
 [http://dx.doi.org/10.1093/jn/112.8.1631]

[164]
Davidek T, Clety N, Devaud S, Robert F, Blank I. Simultaneous quantitative analysis of Maillard reaction precursors and products by high-performance anion exchange chromatography. J Agric Food Chem  2003; 51(25): 7259-65.
 [http://dx.doi.org/10.1021/jf034794n]

[165]
Driscoll DF, Nehne J, Peterss H, Klütsch K, Bistrian BR, Niemann W. Physicochemical stability of intravenous lipid emulsions as all-in-one admixtures intended for the very young. Clin Nutr 2003.
 [http://dx.doi.org/10.1016/S0261-5614(03)00046-3]

[166]
Driscoll DF. Total nutrient admixtures: Theory and practice. Nutr Clin Pract  1995; 10(3): 114-9.
 [http://dx.doi.org/10.1177/0115426595010003114] [PMID: 7616931]

[167]
Brown R, Quercia RA, Sigman R. Total nutrient admixture: A review. JPEN J Parenter Enteral Nutr  1986; 10(6): 650-8.
 [http://dx.doi.org/10.1177/0148607186010006650]

[168]
Driscoll DF, Silvestri AP, Bistrian BR. Stability of MCT/LCT-based total nutrient admixtures for neonatal use over 30 hours at room temperature: Applying pharmacopeial standards. JPEN J Parenter Enteral Nutr  2010; 34(3): 305-12.
 [http://dx.doi.org/10.1177/0148607109338215] [PMID: 20467013]

[169]
Washington C. The stability of intravenous fat emulsions in total parenteral nutrition mixtures. Int J Pharm  1990; 66((1-3)): 1-21.
 [http://dx.doi.org/10.1016/0378-5173(90)90379-I]

[170]
Hardy G, Puzovic M. Formulation, stability, and administration of parenteral nutrition with new lipid emulsions. Nutr Clin Pract  2009; 24(5): 616-25.
 [http://dx.doi.org/10.1177/0884533609342445] [PMID: 19841249]

[171]
Mckinnon BT. FDA safety alert: Hazards of precipitation associated with parenteral nutrition. Nutr Clin Pract  1996; 11(2): 59-65.
 [http://dx.doi.org/10.1177/011542659601100259] [PMID: 8788339]

[172]
Newton DW, Driscoll DF. Calcium and phosphate compatibility: Revisited again. Am J Health Syst Pharm  2008; 65(1): 73-80.
 [http://dx.doi.org/10.2146/ajhp070138]

[173]
Owen HJ, Gonyon TM, Green JB, et al. Calcium/phosphate solubility curves for premasol and trophamine pediatric parenteral nutrition formulations. J Pediatr Pharmacol Ther  2019; 24(1): 45-52.
 [http://dx.doi.org/10.5863/1551-6776-24.1.45]

[174]
Joy J, Silvestri AP, Franke R, et al. Calcium and phosphate compatibility in low-osmolarity parenteral nutrition admixtures intended for peripheral vein administration. JPEN J Parenter Enteral Nutr  2010; 34(1): 46-54.
 [http://dx.doi.org/10.1177/0148607109338216] [PMID: 19846668]

[175]
Dahl GB, Jeppsson RI, Tengborn HJ. Vitamin stability in a TPN mixture stored in an EVA plastic bag. J Clin Pharm Ther  1986; 11(4): 271-9.
 [http://dx.doi.org/10.1111/j.1365-2710.1986.tb00852.x] [PMID: 3093536]

[176]
Domellöf M, Szitanyi P, Simchowitz V, et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Iron and trace minerals. Clin Nutr  2018; 37(6): 2354-9.
 [http://dx.doi.org/10.1016/j.clnu.2018.06.949]

[177]
Postaire E. Stability and behaviour of selenium in total parenteral nutrition solutions. Int J Pharm  1989; 55((2-3)): 99-103.
 [http://dx.doi.org/10.1016/0378-5173(89)90029-X]

[178]
Aksoy GK, Koyun M, Çomak E, Akman S. Severe anemia and massive proteinuria in a boy with diabetes mellitus: Answers. Pediatr Nephrol  2023; 38(9): 2997-9.
 [http://dx.doi.org/10.1007/s00467-023-05972-4] [PMID: 37084136]

[179]
Porcelli PJ, O’Shea TM, Dillard RG. A linear regression model to predict the pH of neonatal parenteral nutrition solution. J Clin Pharm Ther  2000; 25(1): 55-9.
 [http://dx.doi.org/10.1046/j.1365-2710.2000.00263.x] [PMID: 10771464]

[180]
Driscoll DF. Physicochemical assessment of total nutrient admixture stability and safety: Quantifying the risk. Nutrition  1997; 13(2): 166-7.
 [http://dx.doi.org/10.1016/S0899-9007(96)00394-2]

[181]
Steger PJ, Mühlebach SF. in vitro oxidation of iv lipid emulsions in different all-in-one admixture bags assessed by an iodometric assay and gas-liquid chromatography. Nutrition  1997; 13(2): 133-40.
 [http://dx.doi.org/10.1016/S0899-9007(96)00387-5]

[182]
Ball PA, Barnett MI. The dissolved oxygen content of parenteral nutrition admixtures prepared by different methods. Pharm Pharmacol Commun  1996; 2(7): 349-51.
 [http://dx.doi.org/10.1111/j.2042-7158.1996.tb00629.x]

[183]
Allwood MC, Plane JH. The wavelength-dependent degradation of vitamin A exposed to ultraviolet radiation. Int J Pharm  1986; 31(1-2): 1-7.
 [http://dx.doi.org/10.1016/0378-5173(86)90206-1]

[184]
White RD, Smith JA, Shepley MM. Recommended standards for newborn ICU design, eighth edition. J Perinatol  2013; 33(S1): S2-S16.
 [http://dx.doi.org/10.1038/jp.2013.10] [PMID: 23536026]

[185]
Robinson LA, Wright BT. Central venous catheter occlusion caused by body-heat-mediated calcium phosphate precipitation. Am J Health Syst Pharm  1982; 39(1): 120-.
 [http://dx.doi.org/10.1093/ajhp/39.1.120]

[186]
Acramel A, Berrabah S, Postaire M, et al. SUN-P192: Drugs compatibility with parenteral nutrition. Clin Nutr  2016; 35(35): S116.
 [http://dx.doi.org/10.1016/S0261-5614(16)30535-0]

[187]
Davies KJ, Delsignore ME, Lin SW. Protein damage and degradation by oxygen radicals. II. Modification of amino acids. J Biol Chem  1987; 262(20): 9902-7.
 [http://dx.doi.org/10.1016/S0021-9258(18)48019-2]

[188]
Black CD, Popovich NG, Roy M. A study of intravenous emulsion compatibility: Effects of dextrose, amino acids, and selected electrolytes. Drug Intell Clin Pharm  1981; 15(3): 184-93.
 [http://dx.doi.org/10.1177/106002808101500304] [PMID: 7274033]

[189]
Didier ME, Fischer S, Maki DG. Total nutrient admixtures appear safer than lipid emulsion alone as regards microbial contamination: Growth properties of microbial pathogens at room temperature. JPEN J Parenter Enteral Nutr  1998; 22(5): 291-6.
 [http://dx.doi.org/10.1177/0148607198022005291] [PMID: 9739032]

[190]
Zorzetto G, Barzan D, Marzaro G, Pigozzo S, Valenti A. One-chamber and two-chamber parenteral nutrition admixtures for pediatric and adult patients: An evaluation of physico-chemical stability at room and cold temperature. Nutrition  2023; 106: 111891.
 [http://dx.doi.org/10.1016/j.nut.2022.111891]

[191]
Crews J, Rueda-de-Leon E, Remus D, Sayles R, Mateus J, Shakeel F. Total parenteral nutrition standardization and electronic ordering to reduce errors: A quality improvement initiative. Pediatr Qual Saf  2018; 3(4): e093.
 [http://dx.doi.org/10.1097/pq9.0000000000000093] [PMID: 30229203]

[192]
Li S, Nussbaum MS, Teague D, Gapen CL, Dayal R, Fischer JE. Increasing dextrose concentrations in total parenteral nutrition (TPN) causes alterations in hepatic morphology and plasma levels of insulin and glucagon in rats. J Surg Res  1988; 44(6): 639-48.
 [http://dx.doi.org/10.1016/0022-4804(88)90095-9] [PMID: 3132573]

[193]
Gomis P, Arrieta M, Rosas CR, Spiers S, Shinn M, Orbaneja MA. Influence of the type of amino acids in the formation of precipitates of copper and sulphur in parenteral nutrition. Clin Nutr  2018; 37: S256.
 [http://dx.doi.org/10.1016/j.clnu.2018.06.1905]

[194]
Karthigesu K, Bertolo RF, Brown RJ. Parenteral nutrition and oxidant load in neonates. Nutrients  2021; 13(8): 2631.
 [http://dx.doi.org/10.3390/nu13082631]

[195]
Ang SD, Canham JE, Daly JM. Parenteral infusion with an admixture of amino acids, dextrose, and fat emulsion solution: Compatibility and clinical safety. JPEN J Parenter Enteral Nutr  1987; 11(1): 23-7.
 [http://dx.doi.org/10.1177/014860718701100123] [PMID: 3102777]

[196]
Staven V, Wang S, Grønlie I, Tho I. Development and evaluation of a test program for Y-site compatibility testing of total parenteral nutrition and intravenous drugs. Nutr J  2015; 15(1): 29.
 [http://dx.doi.org/10.1186/s12937-016-0149-x] [PMID: 27000057]

[197]
Wormleighton CV, Catling TB. Stability issues in home parenteral nutrition. Clin Nutr  1998; 17(5): 199-203.
 [http://dx.doi.org/10.1016/S0261-5614(98)80059-9]

[198]
Lumpkin MM. Safety alert: Hazards of precipitation associated with parenteral nutrition. Am J Health Syst Pharm  1994; 51(11): 1427-8.
 [http://dx.doi.org/10.1093/ajhp/51.11.1427]

[199]
Shay DK, Farm LM, Jarvis WR. Respiratory distress and sudden death associated with receipt of a peripheral parenteral nutrition admixture. Infect Control Hosp Epidemiol  1997; 18(12): 814-7.
 [http://dx.doi.org/10.1086/647550] [PMID: 9442405]

[200]
Hardy G, Allwood MC. Formulation of parenteral nutrition regimens. Intestinal Failure. Cham: Springer 2023.
 [http://dx.doi.org/10.1007/978-3-031-22265-8_35]

[201]
Blackmer AB, Partipilo ML. Three-in-one parenteral nutrition in neonates and pediatric patients: Risks and benefits. Nutr Clin Pract  2015; 30(3): 337-43.
 [http://dx.doi.org/10.1177/0884533615580596] [PMID: 25857309]

[202]
Dudrick SJ. Early developments and clinical applications of total parenteral nutrition. JPEN J Parenter Enteral Nutr  2003; 27(4): 291-9.
 [http://dx.doi.org/10.1177/0148607103027004291] [PMID: 12903895]

[203]
Chang HHR, Chen K, Lugtu-Pe JA, et al. Design and optimization of a nanoparticulate pore former as a multifunctional coating excipient for pH transition-independent controlled release of weakly basic drugs for oral drug delivery. Pharmaceutics  2023; 15(2): 547.
 [http://dx.doi.org/10.3390/pharmaceutics15020547] [PMID: 36839869]

[204]
Jawed A, Jawed A, Anis ME, Qadeer MA, Abbas Z. Superior mesenteric artery syndrome: A vicious cycle? ACG Case Rep J  2023; 10(2): e00995.
 [http://dx.doi.org/10.14309/crj.0000000000000995] [PMID: 36846354]

[205]
Kim DH, Lukens FJ, Ko D, et al. Incidence, burden, and predictors of 11-month readmission in patients undergoing bariatric surgery. Obes Surg  2023; 33(1): 94-104.
 [http://dx.doi.org/10.1007/s11695-022-06343-y] [PMID: 36319825]

[206]
Wang P, Sun H, Maitiabula G, et al. Total parenteral nutrition impairs glucose metabolism by modifying the gut microbiome. Nat Metab  2023; 5(2): 331-48.
 [http://dx.doi.org/10.1038/s42255-023-00744-8] [PMID: 36782071]

[207]
Omori NE, Malys MK, Woo G, Mansor L. Exploring the role of ketone bodies in the diagnosis and treatment of psychiatric disorders. Front Psychiatry  2023; 14: 1142682.
 [http://dx.doi.org/10.3389/fpsyt.2023.1142682] [PMID: 37139329]

[208]
Demarest K, Lavu H, Collins E, Batra V. Comprehensive diagnosis and management of malignant bowel obstruction: A review. J Pain Palliat Care Pharmacother  2023; 37(1): 91-105.
 [http://dx.doi.org/10.1080/15360288.2022.2106012] [PMID: 36377820]

[209]
Huang L, Lu J, Shi L, Zhang H. Regulation, production and clinical application of Foods for Special Medical Purposes (FSMPs) in China and relevant application of food hydrocolloids in dysphagia therapy. Food Hydrocoll  2023; 140: 108613.
 [http://dx.doi.org/10.1016/j.foodhyd.2023.108613]

[210]
Parkman HP, Blackford AL, Murray HB, et al. Characteristics and outcomes of patients with gastroparesis using enteral and/or exclusive parenteral nutrition. JPEN J Parenter Enteral Nutr  2023; 47(4): 541-9.
 [http://dx.doi.org/10.1002/jpen.2493] [PMID: 36871132]

[211]
Pohlenz-Saw JAE, Merriweather JL, Wandrag L. (Mal)nutrition in critical illness and beyond: A narrative review. Anaesthesia  2023; 78(6): 770-8.
 [http://dx.doi.org/10.1111/anae.15951] [PMID: 36644786]

[212]
Aldridge TA, Mathias KK, Bergquist JR, Fong YY, Li AY, Visser BC. Utilization of parenteral nutrition in major gastrointestinal surgery: An opportunity for quality improvement. Clin Nutr ESPEN  2023; 57: 233-8.
 [http://dx.doi.org/10.1016/j.clnesp.2023.06.019] [PMID: 37739662]

[213]
Gürünlüoğlu S, Gül M, Gürünlüoğlu K, et al. Histopathological and ultra-structural investigation of the damaging effects of hypoinsulinemia, hyper glycaemia and oxidative stress caused by parenteral nutrition combined with fasting on the small intestine of rabbits. Arab J Gastroenterol  2023; 24(2): 129-35.
 [http://dx.doi.org/10.1016/j.ajg.2023.02.003] [PMID: 36890026]

[214]
Jiang L, Liu Y, Zhou Y, et al. Targeted metabolomics unravels altered phenylalanine levels in piglets receiving total parenteral nutrition. FASEB J  2023; 37(7): e23014.
 [http://dx.doi.org/10.1096/fj.202300261RR] [PMID: 37261736]

[215]
Kubota Y, Han Q, Aoki Y, et al. Synergy of combining methionine restriction and chemotherapy: The disruptive next generation of cancer treatment. Cancer Diagnos Prognosis  2023; 3(3): 272-81.
 [http://dx.doi.org/10.21873/cdp.10212] [PMID: 37168964]

[216]
Pasricha SV, Allard JP, Alqarni KA, Davis MJ, Chan CT. Case studies of intradialytic total parenteral nutrition in nocturnal home hemodialysis. J Ren Nutr  2023; 33(1): 219-22.
 [http://dx.doi.org/10.1053/j.jrn.2022.06.009] [PMID: 35798187]

[217]
Blumenkrantz MJ, Kopple JD, Koffler A, et al. Total parenteral nutrition in the management of acute renal failure. Am J Clin Nutr  1978; 31(10): 1831-40.
 [http://dx.doi.org/10.1093/ajcn/31.10.1831] [PMID: 101071]

[218]
Maudar KK. Total parenteral nutrition. Med J Armed Forces India  1995; 51(2): 122-6.
 [http://dx.doi.org/10.1016/S0377-1237(17)30942-5]

[219]
Firstenberg MS, Kornbau C, Lee KC, Hughes GD. Central line complications. Int J Crit Illn Inj Sci  2015; 5(3): 170-8.
 [http://dx.doi.org/10.4103/2229-5151.164940] [PMID: 26557487]

[220]
To KB, Napolitano LM. Common complications in the critically ill patient. Surg Clin North Am  2012; 92(6): 1519-57.
 [http://dx.doi.org/10.1016/j.suc.2012.08.018]

[221]
Doyle GR, McCutcheon JA. Clinical Procedures for Safer Patient Care Clinical Procedures for Safer Patient Care.  BCcampus 2016; p. 1.

[222]
Hartl WH, Jauch KW, Parhofer K, Rittler P. Complications and monitoring - guidelines on parenteral nutrition, Chapter 11. Ger Med Sci  2009; 7

[223]
Sobotka L, Camilo ME. Basics in clinical nutrition: Metabolic complications of parenteral nutrition. E Spen Eur E J Clin Nutr Metab  2009; 4(3): e120-2.
 [http://dx.doi.org/10.1016/j.eclnm.2009.01.001]

[224]
Shibila S, Rinoy C, Shabana A. Metabolic complications associated with total parenteral nutrition. Asian J Pharm Res Dev  2023; 11(2): 65-8.

[225]
Keefe G, Culbreath K, Knell J, et al. Long-term assessment of bilirubin and transaminase trends in pediatric intestinal failure patients during the era of hepatoprotective parenteral nutrition. J Pediatr Surg  2022; 57(1): 122-6.
 [http://dx.doi.org/10.22270/ajprd.v11i2.1237]

[226]
Peruri GP, Murugesan A, Mondal N, et al. Metabolic bone disease in preterm neonates with fetal growth restriction (FGR): A prospective cohort study. Indian Pediatr  2023; 60(10): 829-33.
 [http://dx.doi.org/10.1007/s13312-023-3014-y] [PMID: 37480295]

[227]
Gatti S, Quattrini S, Palpacelli A, Catassi GN, Lionetti ME, Catassi C. Metabolic bone disease in children with intestinal failure and long-term parenteral nutrition: A systematic review. Nutrients  2022; 14(5): 995.
 [http://dx.doi.org/10.3390/nu14050995]

[228]
Sobh MM, Abdalbary M, Elnagar S, et al. Secondary osteoporosis and metabolic bone diseases. J Clin Med  2022; 11(9): 2382.
 [http://dx.doi.org/10.3390/jcm11092382] [PMID: 35566509]

[229]
Korytkowski MT, Muniyappa R, Antinori-Lent K, et al. Management of hyperglycemia in hospitalized adult patients in non-critical care settings: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab  2022; 107(8): 2101-28.
 [http://dx.doi.org/10.1210/clinem/dgac278] [PMID: 35690958]

[230]
Rajagopalan V, Prabhakar H. Basics of total parenteral nutrition. Transfusion Practice in Clinical Neurosciences.  Springer 2022; pp. 575-84.
 [http://dx.doi.org/10.1007/978-981-19-0954-2_48]

[231]
Cao L, Zhang D, Zhao Y, Zhou N, Zhang P. Efficacy and safety of different insulin infusion methods in the treatment of total parenteral nutrition-associated hyperglycemia: A systematic review and network meta-analysis. Front Nutr  2023; 10: 1181359.
 [http://dx.doi.org/10.3389/fnut.2023.1181359] [PMID: 37674887]
Rights & Permissions Print Cite
Article Metrics
34
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0113894501284598240226102943	Print ISSN 1389-4501
Publisher Name Bentham Science Publisher	Online ISSN 1873-5592
Current Drug Targets

Use of Total Parenteral Nutrition (TPN) as a Vehicle for Drug Delivery

Abstract

Graphical Abstract

Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics

New drug therapy for eye diseases

Therapeutic Chemical and RNA Design with Artificial Intelligence

Current Drug Targets

Use of Total Parenteral Nutrition (TPN) as a Vehicle for Drug Delivery

Abstract

Graphical Abstract

Call for Papers in Thematic Issues

Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics

New drug therapy for eye diseases

Therapeutic Chemical and RNA Design with Artificial Intelligence

Related Journals

Related Books

Related Articles
